Heron Therapeutics Appoints New Chief Medical Officer
Ticker: HRTX · Form: 8-K · Filed: 2024-11-04T00:00:00.000Z
Sentiment: neutral
Topics: executive-appointment, personnel, healthcare
Related Tickers: AMGN
TL;DR
Heron Therapeutics just hired a new CMO from Amgen, signaling a potential shift in their drug development strategy.
AI Summary
Heron Therapeutics, Inc. announced on November 4, 2024, the appointment of Dr. Michael R. Green as Chief Medical Officer. Dr. Green, who previously served as Senior Vice President and Chief Medical Officer at Amgen, brings extensive experience in drug development and medical affairs. This appointment is part of Heron's ongoing efforts to strengthen its leadership team as it advances its pipeline.
Why It Matters
The appointment of a seasoned Chief Medical Officer like Dr. Green can signal a renewed focus on clinical development and regulatory strategy, potentially impacting the company's future drug approvals and market positioning.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially to a critical role like CMO, can introduce uncertainty regarding strategic direction and execution, though it also presents an opportunity for improved performance.
Key Players & Entities
- Heron Therapeutics, Inc. (company) — Registrant
- Dr. Michael R. Green (person) — Appointed Chief Medical Officer
- Amgen (company) — Previous employer of Dr. Green
- November 4, 2024 (date) — Date of report and appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Heron Therapeutics?
Dr. Michael R. Green has been appointed as the new Chief Medical Officer of Heron Therapeutics.
When was this appointment announced?
The appointment was announced on November 4, 2024.
What was Dr. Green's previous role?
Dr. Green previously served as Senior Vice President and Chief Medical Officer at Amgen.
What is Heron Therapeutics' primary business?
Heron Therapeutics, Inc. is involved in the pharmaceutical preparations industry.
Where is Heron Therapeutics headquartered?
Heron Therapeutics, Inc. is headquartered at 4242 Campus Point Court, Suite 200, San Diego, CA 92121.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-11-04 17:09:40
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share HRTX The Nasdaq Capital M
Filing Documents
- hrtx-20241104.htm (8-K) — 62KB
- hrtx-ex99_1.htm (EX-99.1) — 8KB
- 0000950170-24-120902.txt ( ) — 193KB
- hrtx-20241104.xsd (EX-101.SCH) — 30KB
- hrtx-20241104_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 4, 2024, the Company issued a press release with respect to the matters described in this Current Report on Form 8-K and such press release is attached hereto and furnished as Exhibit 99.1. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Heron Therapeutics, Inc. Date: November 4, 2024 /s/ Ira Duarte Ira Duarte Executive Vice President, Chief Financial Officer